Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Spada M et al. | Randomized trial of basiliximab induction versus steroid therapy in pediatric liver allograft recipients under tacrolimus immunosuppression. | 2006 | Am. J. Transplant. | pmid:16771811 |
Kim EJ et al. | Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection. | 2014 | Am. J. Transplant. | pmid:24354871 |
Kandaswamy R et al. | A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients--an interim analysis. | 2005 | Am. J. Transplant. | pmid:15888064 |
Saliba F et al. | Efficacy and Safety of Everolimus and Mycophenolic Acid With Early Tacrolimus Withdrawal After Liver Transplantation: A Multicenter Randomized Trial. | 2017 | Am. J. Transplant. | pmid:28133906 |
Cosio FG and Larson TS | Cardiovascular disease after transplantation: do we know all of the variables? | 2003 | Am. J. Transplant. | pmid:12859523 |
Levitsky J and Feng S | Sirolimus and mTOR inhibitors in liver transplantation: the wheel has come full circle. | 2014 | Am. J. Transplant. | pmid:24620373 |
de Fijter JW et al. | Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial. | 2017 | Am. J. Transplant. | pmid:28027625 |
Krämer BK et al. | Cardiovascular risk factors and estimated risk for CAD in a randomized trial comparing calcineurin inhibitors in renal transplantation. | 2003 | Am. J. Transplant. | pmid:12859533 |
Ciancio G et al. | The use of daclizumab, tacrolimus and mycophenolate mofetil in african-american and Hispanic first renal transplant recipients. | 2003 | Am. J. Transplant. | pmid:12859538 |
Trofe-Clark J et al. | Immunosuppression, generic drugs and the FDA. | 2012 | Am. J. Transplant. | pmid:22176626 |
Xu H et al. | The allo- and viral-specific immunosuppressive effect of belatacept, but not tacrolimus, attenuates with progressive T cell maturation. | 2014 | Am. J. Transplant. | pmid:24472192 |
Boudjema K et al. | Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study. | 2011 | Am. J. Transplant. | pmid:21466650 |
Coghill AE et al. | Immunosuppressive Medications and Squamous Cell Skin Carcinoma: Nested Case-Control Study Within the Skin Cancer after Organ Transplant (SCOT) Cohort. | 2016 | Am. J. Transplant. | pmid:26824445 |
Knechtle SJ | Guidance for liver transplant immunosuppression. | 2011 | Am. J. Transplant. | pmid:21466652 |
Asrani SK et al. | De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial. | 2014 | Am. J. Transplant. | pmid:24456026 |
Song L et al. | ASP2409, A Next-Generation CTLA4-Ig, Versus Belatacept in Renal Allograft Survival in Cynomolgus Monkeys. | 2017 | Am. J. Transplant. | pmid:27598231 |
Saikali JA et al. | Sirolimus may promote thrombotic microangiopathy. | 2003 | Am. J. Transplant. | pmid:12603218 |
Mehra MR et al. | Immunosuppression in cardiac transplantation: science, common sense and the heart of the matter. | 2006 | Am. J. Transplant. | pmid:16686745 |
Grimm M et al. | Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients--a large European trial. | 2006 | Am. J. Transplant. | pmid:16686762 |
Budde K et al. | Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial. | 2014 | Am. J. Transplant. | pmid:25278376 |
Sis B et al. | Reproducibility studies on arteriolar hyaline thickening scoring in calcineurin inhibitor-treated renal allograft recipients. | 2006 | Am. J. Transplant. | pmid:16686769 |
Duncan FJ et al. | Clinically relevant immunosuppressants influence UVB-induced tumor size through effects on inflammation and angiogenesis. | 2007 | Am. J. Transplant. | pmid:17941958 |
Hu X et al. | Chimeric Allografts Induced by Short-Term Treatment With Stem Cell-Mobilizing Agents Result in Long-Term Kidney Transplant Survival Without Immunosuppression: A Study in Rats. | 2016 | Am. J. Transplant. | pmid:26749344 |
Cameron AM et al. | Chimeric Allografts Induced by Short-Term Treatment With Stem Cell Mobilizing Agents Result in Long-Term Kidney Transplant Survival Without Immunosuppression: II, Study in Miniature Swine. | 2016 | Am. J. Transplant. | pmid:26748958 |
O'Grady JG et al. | Randomized controlled trial of tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: poststudy surveillance to 3 years. | 2007 | Am. J. Transplant. | pmid:17109723 |
Böhmig GA et al. | Immunoadsorption in severe C4d-positive acute kidney allograft rejection: a randomized controlled trial. | 2007 | Am. J. Transplant. | pmid:17109725 |
Ferguson R et al. | Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. | 2011 | Am. J. Transplant. | pmid:21114656 |
McKenna G and Trotter JF | Does early (CNI) conversion lead to eternal (renal) salvation? | 2010 | Am. J. Transplant. | pmid:20928938 |
Bouamar R et al. | Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: a pooled analysis from three randomized-controlled clinical trials(†). | 2013 | Am. J. Transplant. | pmid:23480233 |
Busque S et al. | The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation. | 2011 | Am. J. Transplant. | pmid:21943027 |
Hamdy AF et al. | Comparison of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantation. | 2005 | Am. J. Transplant. | pmid:16162204 |
Kaufman DB et al. | Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction--long-term results. | 2005 | Am. J. Transplant. | pmid:16162205 |
Naesens M et al. | Tacrolimus exposure and evolution of renal allograft histology in the first year after transplantation. | 2007 | Am. J. Transplant. | pmid:17608835 |
Schwarz A et al. | Polyoma virus nephropathy in native kidneys after lung transplantation. | 2005 | Am. J. Transplant. | pmid:16162212 |
Koefoed-Nielsen PB et al. | Blood tacrolimus levels and calcineurin phosphatase activity early after renal transplantation. | 2002 | Am. J. Transplant. | pmid:12099520 |
Klintmalm GB | Immunosuppression, generic drugs and the FDA. | 2011 | Am. J. Transplant. | pmid:21794082 |
Shemesh E et al. | The Medication Level Variability Index (MLVI) Predicts Poor Liver Transplant Outcomes: A Prospective Multi-Site Study. | 2017 | Am. J. Transplant. | pmid:28321975 |
Forns X and Navasa M | Cyclosporine A or tacrolimus for hepatitis C recurrence? An old debate. | 2011 | Am. J. Transplant. | pmid:21797970 |
Wlodarczyk Z et al. | Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial. | 2009 | Am. J. Transplant. | pmid:19681813 |
Chisholm-Burns MA et al. | Immunosuppressant therapy adherence and graft failure among pediatric renal transplant recipients. | 2009 | Am. J. Transplant. | pmid:19681814 |
Schold JD and Kaplan B | AZA/tacrolimus is associated with similar outcomes as MMF/tacrolimus among renal transplant recipients. | 2009 | Am. J. Transplant. | pmid:19681827 |
Willicombe M et al. | Outcome of patients with preformed donor-specific antibodies following alemtuzumab induction and tacrolimus monotherapy. | 2011 | Am. J. Transplant. | pmid:21299828 |
Pirenne J et al. | Tolerance of liver transplant patients to strenuous physical activity in high-altitude. | 2004 | Am. J. Transplant. | pmid:15023147 |
Heisel O et al. | New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. | 2004 | Am. J. Transplant. | pmid:15023151 |
Hardinger KL et al. | Pharmacokinetics of tacrolimus in kidney transplant recipients: twice daily versus once daily dosing. | 2004 | Am. J. Transplant. | pmid:15023155 |
Suwelack B et al. | Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. | 2004 | Am. J. Transplant. | pmid:15023160 |
Madariaga ML et al. | Kidney-induced cardiac allograft tolerance in miniature swine is dependent on MHC-matching of donor cardiac and renal parenchyma. | 2015 | Am. J. Transplant. | pmid:25824550 |
Vanrenterghem Y et al. | Minimization of immunosuppressive therapy after renal transplantation: results of a randomized controlled trial. | 2005 | Am. J. Transplant. | pmid:15636615 |
Bryan CF et al. | Long-term survival of kidneys transplanted from live A2 donors to O and B recipients. | 2007 | Am. J. Transplant. | pmid:17359511 |
Vincenti F et al. | Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. | 2007 | Am. J. Transplant. | pmid:17359512 |
Busque S et al. | Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients. | 2009 | Am. J. Transplant. | pmid:19660021 |
Diaz-Siso JR et al. | Initial experience of dual maintenance immunosuppression with steroid withdrawal in vascular composite tissue allotransplantation. | 2015 | Am. J. Transplant. | pmid:25777324 |
Cendales L et al. | Tacrolimus to Belatacept Conversion Following Hand Transplantation: A Case Report. | 2015 | Am. J. Transplant. | pmid:25773260 |
Rodriguez-Rodriguez AE et al. | The higher diabetogenic risk of tacrolimus depends on pre-existing insulin resistance. A study in obese and lean Zucker rats. | 2013 | Am. J. Transplant. | pmid:23651473 |
Klintmalm GB et al. | Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study. | 2014 | Am. J. Transplant. | pmid:25041339 |
Jaksch P et al. | Alemtuzumab in lung transplantation: an open-label, randomized, prospective single center study. | 2014 | Am. J. Transplant. | pmid:25039364 |
TruneÄŒka P et al. | Renal Function in De Novo Liver Transplant Recipients Receiving Different Prolonged-Release Tacrolimus Regimens-The DIAMOND Study. | 2015 | Am. J. Transplant. | pmid:25707487 |
Adam R et al. | Improved survival in liver transplant recipients receiving prolonged-release tacrolimus in the European Liver Transplant Registry. | 2015 | Am. J. Transplant. | pmid:25703527 |
Asrani SK and O'Leary JG | Can one pill a day keep rejection away? | 2015 | Am. J. Transplant. | pmid:25703394 |
Bhorade SM et al. | Comparison of three tacrolimus-based immunosuppressive regimens in lung transplantation. | 2003 | Am. J. Transplant. | pmid:14629288 |
Oetting WS et al. | Genomewide Association Study of Tacrolimus Concentrations in African American Kidney Transplant Recipients Identifies Multiple CYP3A5 Alleles. | 2016 | Am. J. Transplant. | pmid:26485092 |
Badri P et al. | Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. | 2015 | Am. J. Transplant. | pmid:25708713 |
Chodoff L and Hamberg KJ | Response to 'Different preparations of tacrolimus and medication errors'. | 2009 | Am. J. Transplant. | pmid:19392982 |
Larson TS et al. | Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. | 2006 | Am. J. Transplant. | pmid:16468960 |
Vitko S et al. | Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter study. | 2006 | Am. J. Transplant. | pmid:16468962 |
Barth RN et al. | Vascularized bone marrow-based immunosuppression inhibits rejection of vascularized composite allografts in nonhuman primates. | 2011 | Am. J. Transplant. | pmid:21668624 |
Guirado L et al. | Efficacy and safety of conversion from twice-daily to once-daily tacrolimus in a large cohort of stable kidney transplant recipients. | 2011 | Am. J. Transplant. | pmid:21668633 |
Flechner SM et al. | The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. | 2011 | Am. J. Transplant. | pmid:21668635 |
Budde K | How to use mTOR inhibitors? The search goes on. | 2011 | Am. J. Transplant. | pmid:21668636 |
Luan FL et al. | Comparative risk of impaired glucose metabolism associated with cyclosporine versus tacrolimus in the late posttransplant period. | 2008 | Am. J. Transplant. | pmid:18786231 |
Woywodt A et al. | Different preparations of tacrolimus and medication errors. | 2008 | Am. J. Transplant. | pmid:18786238 |
Carenco C et al. | Tacrolimus and the risk of solid cancers after liver transplant: a dose effect relationship. | 2015 | Am. J. Transplant. | pmid:25648361 |
Maes BD et al. | Differential effect of diarrhea on FK506 versus cyclosporine A trough levels and resultant prevention of allograft rejection in renal transplant recipients. | 2002 | Am. J. Transplant. | pmid:12484345 |
Ogawa T et al. | Rho-associated kinase inhibitor reduces tumor recurrence after liver transplantation in a rat hepatoma model. | 2007 | Am. J. Transplant. | pmid:17229077 |
Miriuka SG et al. | mTOR inhibition induces endothelial progenitor cell death. | 2006 | Am. J. Transplant. | pmid:16796720 |
Bourdeaux C et al. | Living-related versus deceased donor pediatric liver transplantation: a multivariate analysis of technical and immunological complications in 235 recipients. | 2007 | Am. J. Transplant. | pmid:17173657 |
Heller T et al. | Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients. | 2007 | Am. J. Transplant. | pmid:17532750 |
Schrepfer S et al. | Effect of inhaled tacrolimus on cellular and humoral rejection to prevent posttransplant obliterative airway disease. | 2007 | Am. J. Transplant. | pmid:17532751 |
Grenda R et al. | A randomized trial to assess the impact of early steroid withdrawal on growth in pediatric renal transplantation: the TWIST study. | 2010 | Am. J. Transplant. | pmid:20420639 |
Knechtle SJ et al. | Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring. | 2009 | Am. J. Transplant. | pmid:19344431 |
Asberg A et al. | Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients. | 2010 | Am. J. Transplant. | pmid:20486914 |
Hautz T et al. | Molecular markers and targeted therapy of skin rejection in composite tissue allotransplantation. | 2010 | Am. J. Transplant. | pmid:20353468 |
Rostaing L et al. | Alefacept combined with tacrolimus, mycophenolate mofetil and steroids in de novo kidney transplantation: a randomized controlled trial. | 2013 | Am. J. Transplant. | pmid:23730730 |
Grinyo JM et al. | Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation. | 2004 | Am. J. Transplant. | pmid:15268733 |
Pallet N et al. | Kidney transplant recipients carrying the CYP3A4*22 allelic variant have reduced tacrolimus clearance and often reach supratherapeutic tacrolimus concentrations. | 2015 | Am. J. Transplant. | pmid:25588704 |
Schussler T et al. | Severe hepatitis C infection in a renal transplant recipient following hepatitis C genotype mismatch transplant. | 2004 | Am. J. Transplant. | pmid:15268744 |
Toso C et al. | Sequential kidney/islet transplantation: efficacy and safety assessment of a steroid-free immunosuppression protocol. | 2006 | Am. J. Transplant. | pmid:16611343 |
Lacaille F et al. | Severe dysimmune cytopenia in children treated with tacrolimus after organ transplantation. | 2006 | Am. J. Transplant. | pmid:16611346 |
Chamie K et al. | The effect of sirolimus on prostate-specific antigen (PSA) levels in male renal transplant recipients without prostate cancer. | 2008 | Am. J. Transplant. | pmid:18853950 |
Lefaucheur C et al. | Renal histopathological lesions after lung transplantation in patients with cystic fibrosis. | 2008 | Am. J. Transplant. | pmid:18671673 |
Levy G et al. | REFINE: a randomized trial comparing cyclosporine A and tacrolimus on fibrosis after liver transplantation for hepatitis C. | 2014 | Am. J. Transplant. | pmid:24456049 |
Haufroid V et al. | CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. | 2006 | Am. J. Transplant. | pmid:17049058 |
Ciancio G et al. | Advantage of rapamycin over mycophenolate mofetil when used with tacrolimus for simultaneous pancreas kidney transplants: randomized, single-center trial at 10 years. | 2012 | Am. J. Transplant. | pmid:22946986 |
Jacobson PA et al. | Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs. | 2012 | Am. J. Transplant. | pmid:22947444 |
De Simone P et al. | Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. | 2012 | Am. J. Transplant. | pmid:22882750 |
Lake JR et al. | Addition of MMF to dual immunosuppression does not increase the risk of malignant short-term death after liver transplantation. | 2005 | Am. J. Transplant. | pmid:16303011 |
Fujishiro J et al. | Influence of immunosuppression on alloresponse, inflammation and contractile function of graft after intestinal transplantation. | 2010 | Am. J. Transplant. | pmid:20642681 |
Margreiter R et al. | Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial. | 2008 | Am. J. Transplant. | pmid:18510632 |
Martinez F et al. | High dose epoetin beta in the first weeks following renal transplantation and delayed graft function: Results of the Neo-PDGF Study. | 2010 | Am. J. Transplant. | pmid:20642691 |
Mandelbrot DA et al. | Effect of Ramipril on Urinary Protein Excretion in Maintenance Renal Transplant Patients Converted to Sirolimus. | 2015 | Am. J. Transplant. | pmid:26176342 |